Every day, cancer patients endure toxic treatments that won’t work for them. Despite billions invested in cancer research, treatment selection remains primitive trial-and-error medicine. Two-thirds of cancer drugs fail for any given patient, discovered only after weeks of suffering and tens of thousands of wasted costs. For patients with rare or relapsed cancers, this broken approach often means running out of time before finding effective treatment. This system costs lives, creates unnecessary suffering, and wastes $150 billion annually on ineffective therapies.
The fundamental problem is that current cancer treatment relies on population averages rather than individual biology. Genomic testing identifies actionable targets in only 30% of cancers, leaving most patients in a medical guessing game. Existing functional testing platforms are inadequate – too slow at 35+ days, testing too few drugs at 12-14 compounds, and critically, they ignore normal tissue toxicity, missing the complete picture needed for optimal treatment selection.
Biocerta Precision Diagnostics has developed a revolutionary solution that transforms cancer care from educated guessing to precision medicine. Our functional drug-sensitivity platform tests fresh tumor tissue against over 200 FDA-approved compounds in just 14 days, uniquely comparing cancer cell death with normal tissue response. This breakthrough dual assessment – impossible with current genomic approaches – identifies drugs that kill tumors while sparing healthy cells, solving both efficacy and toxicity challenges simultaneously. Our proprietary scoring algorithm delivers actionable, personalized treatment recommendations when patients need them most.
We’ve built insurmountable competitive advantages that position us as the clear market leader. Our drug library is 15 times larger than that of our closest competitors, with 200+ compounds versus their 12-14. We deliver results 2.5 times faster with our 14-day turnaround compared to 35+ days for alternatives. We’re the only platform assessing normal tissue toxicity, providing critical safety insights that others cannot. Our unit economics are superior, with an 87% cost advantage at $28 per compound, compared with competitors’ $52-216. Most importantly, we’ve demonstrated clinical superiority, achieving a 60% response rate compared with 0% with standard approaches in challenging cases.
Our clinical validation has been remarkable. Among patients with relapsed leukemia for whom standard approaches achieved no responses, 3 of 5 responded to DST-guided treatment. In pediatric sarcoma, 10 patients achieved tumor necrosis rates exceeding 90% per our recommendations. These results prove our platform’s transformative potential in the most challenging cases where patients have exhausted other options.
The market opportunity is massive and expanding rapidly. The $11.6 billion drug sensitivity testing market is accelerating as precision medicine adoption grows. We’re strategically targeting the $1.2 billion rare cancer segment first, where unmet medical need is highest and willingness to pay is strongest. This staged approach generates early revenue while building clinical evidence to support broader market penetration across all oncology indications.
Our business model creates multiple revenue pathways beyond clinical testing. We’re building toward our ultimate vision of mandatory DST before any chemotherapy – achieving insurance mandate status where our test becomes standard-of-care. Additional opportunities include pharma partnerships for drug development, research collaborations for target validation, and expansion into veterinary oncology to generate early revenue while pursuing human-market insurance coverage.
Led by scientific leaders with exclusive licensing and peer-reviewed publications, Arbitrage offers investors a validated technology addressing an urgent market need. Our de-risked path through rare cancers provides financial runway while demonstrating platform capabilities. The potential to reduce cancer treatment costs by 70% through the prevention of ineffective therapies aligns well with healthcare economics trends and payer priorities.
Biocerta Precision Diagnostics represents the next evolution in cancer care – from population averages to individual precision. We’re not just improving outcomes; we’re saving lives, reducing suffering, and cutting costs. The time for functional drug sensitivity testing has arrived, and we’re uniquely positioned to lead this transformation. We’re seeking strategic partners and investors who share our vision of ending cancer’s guessing game forever, ensuring every patient receives the right treatment from day one rather than after months of trial-and-error.
